文献速递精神分裂症与精神病性障碍

从未用药精神病患者不同疾病阶段的内侧前额叶谷氨酸水平

Glutamate Levels in Medial Prefrontal Cortex According to Illness Phase of Never-Medicated Individuals With Psychosis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项横断面研究用质子磁共振波谱比较了从未用药的首发非情感性精神病患者、慢性精神分裂症患者和健康对照的内侧前额叶谷氨酸水平。结果显示首发精神病组谷氨酸水平高于慢性精神分裂症组和对照组,而慢性组与对照组无显著差异;首发组中较高的谷氨酸水平与较低的语言和视觉学习评分相关。

要点

  • 从未用药的首发精神病患者内侧前额叶谷氨酸水平高于健康对照和慢性精神分裂症患者。
  • 慢性精神分裂症患者与健康对照的谷氨酸水平无显著差异。
  • 首发精神病患者中较高的谷氨酸水平与较差的语言和视觉学习表现相关。

核心结论

  • 内侧前额叶谷氨酸水平的差异可能主要出现在疾病早期阶段。
  • 研究结果对重新开展靶向代谢型谷氨酸受体2/3激动剂的临床试验具有启示,需考虑疾病阶段和磁共振波谱测得的谷氨酸能改变。

研究设计与样本

  • 横断面研究,使用质子磁共振波谱测量内侧前额叶谷氨酸水平。
  • 纳入181人:65例首发非情感性精神病、42例慢性精神分裂症、74例年龄和性别匹配的健康对照。
  • 因过度运动或波谱质量差排除38例参与者数据(14例首发、10例精神分裂症、14例对照),最终分析83例患者和60例对照。
  • 研究对象来自墨西哥城Instituto Nacional de Neurología y Neurocirugía的住院和门诊服务,时间范围为2017年11月至2025年7月。

主要发现

  • 三组间谷氨酸水平存在差异(F2,136 = 7.5;P = .001)。
  • 首发精神病组谷氨酸水平高于慢性精神分裂症组(P = .003;Cohen d = 0.69)和对照组(P = .008;Cohen d = 0.83)。
  • 慢性精神分裂症组与对照组谷氨酸水平无显著差异(P > .99)。
  • 首发精神病组中较高的谷氨酸水平与较低的语言学习评分相关(ρ = -0.29;P = .04)。
  • 首发精神病组中较高的谷氨酸水平与较低的视觉学习评分相关(ρ = -0.29;P = .04)。

关键数值与推荐

  • 主要结局为谷氨酸水平以及阳性与阴性症状综合征量表(PANSS)和MATRICS共识认知成套测验(MCCB)的评分。
  • 首发精神病组平均(SD)年龄为25.9(7.2)岁,慢性精神分裂症组为38.0(14.5)岁,对照组为30.4(11.5)岁。
  • 性别分布无差异:首发精神病组男性34例(67.0%),慢性精神分裂症组男性20例(62.5%),对照组男性33例(55.0%);P = .44。

临床怎么用

  • 临床评估谷氨酸能改变时应考虑疾病阶段,首发精神病阶段可能更明显。
  • 未来靶向代谢型谷氨酸受体2/3激动剂的临床试验设计需结合疾病阶段和磁共振波谱测得的谷氨酸能改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence suggests that elevated glutamate levels in the medial prefrontal cortex may be associated with the illness stage, but little is known about whether these effects occur in the absence of antipsychotic treatment. OBJECTIVE: To evaluate differences in glutamate levels in treatment-naive individuals with psychosis on the schizophrenia spectrum at different stages of the illness. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study uses proton magnetic resonance spectroscopy in the medial prefrontal cortex of individuals experiencing their first episode of nonaffective psychosis, individuals with chronic schizophrenia, and matched controls at inpatient and outpatient services of the Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico, from November 2017 to July 2025. Data were analyzed from January 28, 2025, to August 8, 2025. EXPOSURE: Proton magnetic resonance spectroscopy. MAIN OUTCOMES AND MEASURES: The primary outcome was glutamate levels and scores measured on the Positive and Negative Syndrome Scale for Schizophrenia and the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery. RESULTS: This cross-sectional study included a total of 181 individuals (65 with first-episode psychosis [FEP], 42 with chronic schizophrenia, and 74 age- and sex-matched healthy controls). Data from 38 participants (14 with FEP, 10 with schizophrenia, and 14 controls) were rejected from all analyses due to excessive movement or poor spectral quality, leaving 83 participants and 60 controls. The mean (SD) age was 25.9 (7.2) years for individuals with FEP, 38.0 (14.5) years for those with chronic schizophrenia, and 30.4 (11.5) years for controls. Sex distribution did not differ (34 male individuals with FEP [67.0%]; 20 male individuals with chronic schizophrenia [62.5%]; and 33 male controls [55.0%]; P = .44). Glutamate levels differed among the 3 groups (F2,136 = 7.5; P = .001). Post hoc pairwise comparisons revealed higher glutamate levels in the FEP group compared with both the chronic schizophrenia group (P = .003; Cohen d = 0.69) and the control group (P = .008; Cohen d = 0.83). There were no significant differences in glutamate levels between the chronic schizophrenia group and the control group (P > .99). Higher glutamate levels were associated with lower verbal (ρ = -0.29; P = .04) and visual learning scores (ρ = -0.29; P = .04) in the FEP group. CONCLUSIONS AND RELEVANCE: These findings suggest that the differences in glutamate levels may indicate that these alterations occur primarily in the early stages of the disease. The results of this study have implications for resuming clinical trials with targeted metabotropic glutamate receptor 2/3 agonists, taking into account both the disease phase and the glutamatergic alterations measured by magnetic resonance imaging.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rivera-Chávez LF, González-Sangabriel D, González-Manríquez L, et al. Glutamate Levels in Medial Prefrontal Cortex According to Illness Phase of Never-Medicated Individuals With Psychosis. JAMA Psychiatry. 2026. PMID: 41499104. doi:10.1001/jamapsychiatry.2025.4091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。